Effects of pomegranate supplement on menopausal symptoms and quality of life in menopausal women: A double-blind randomized placebo-controlled trial

BackgroundMenopausal symptoms have negative effects on the aspects of quality of life and impose a high cost on the health system. In traditional Persian medicine, pomegranate is recommended to alleviate menopausal symptoms.Material and methodsA randomized double-blind placebo-controlled trial was performed among 78 healthy women. Participants were interviewed three times: Before receiving the supplement/placebo, after completing the treatment, and after 3 weeks with no intervention. They filled out the demographic information sheet, modified-Kupperman index, and Menopause-Specific Quality of Life (MENQOL) questionnaires.ResultsThe mean scores of the modified-Kupperman index and MENQOL characteristics before and after the treatment and after the follow-up period were significantly different between pomegranate and placebo groups in both modified-Kupperman and MENQOL scores (p < 0.001).ConclusionThis study demonstrated that 4 weeks' treatment with the pomegranate supplement significantly ameliorates the irritating symptoms of menopause and improves the quality of life in menopausal women even after 4 weeks' medicine deprivation.     

Depression in a Patient With Alzheimer Disease

This is a case study of a 73-year-old woman recently diagnosed with Alzheimer disease living in an assisted living facility who presented to an outpatient behavioral health clinic with her son for evaluation and treatment of depression. This article highlights the presentation of depression (a diagnosis) versus apathy (a symptom of Alzheimer disease) and the need to assess for co-occurring mood disorders that warrant pharmacologic intervention as well as treatment for cognitive decline in Alzheimer disease.     

Lung Cancer in the Non-smoker: A Patient View Focused on the Hopes and Challenges Facing the Non-smoker Population

A patient view paper focused on hopes and challenges facing the never smoker lung cancer population – from lived experience, unexpected diagnosis, treatment and subsequent immersion in lung cancer research and patient advocacy over many years, citing examples, references and events organised to explore the subject by UK research institutions.Material/methodsBased on lived experience, invited patient perspective conference presentations including National Cancer Research Institute (NCRI) never smoker lung cancer research strategy event opening presentation and subsequent article, includes references to relevant papers/findings and points raised during research events/group discussions, alongside personal experiences and beliefs.ResultsDiscussions with clinicians, events, surveys, meetings and virtual discussions all revealed a dearth of evidence available to identify the best way to deal with this patient cohort at almost every aspect of their experience – from missed/late diagnosis, to screening potential (non-existent), mutation driven treatments (what about those ineligible?), and psychosocial/psychological aspects given their different life stage from older traditional lung cancer patients.ConclusionMore effort and focus are needed to better understand what is driving these cases, how best to detect them sooner and respond/refer to treatments as well as developing screening methods alongside increased public and healthcare professional awareness raising and tools to support clinicians in earlier detection.     

Usefulness of discography,discoblock and a new mechanical method for identifying a painful segment/disc

BackgroundWe previously described a procedure for eliciting deep spatial discrimination of individual segments in the healthy lumbar spine of normal subjects: the percutaneous mechanical provocation (PMP) test. Our goal was to devise a method for accurate identification of the spinal level of pathology in chronic low back pain (CLBP). In the present study, we validated the PMP test, using a subgroup of CLBP patients with isthmic spondylolisthesis (IS). Because there is clinical consensus that IS back pain originates in the slipped segment/disc, the level of pathology can be directly compared to the result of the PMP test. The test is agnostic with respect to the underlying pathological mechanism, and therefore might be useful in identifying the involved segment(s) irrespective of the painful structure.MethodsIn 37 patients with confirmed IS (slippage 3–15 mm), we compared sensitivity between the PMP test, the widely used provocative discography test and the discoblock test.ResultsThe PMP test reliably identified the slip level in patients with IS, with sensitivity of 92%. Accepting the slipped disc as the origin of pain in IS, the sensitivity of the provocative discography and discoblock tests were 49% and 35%, respectively: i.e., too low to be contributive in clinical practice.ConclusionsThe PMP test reliably identified the origin of localized pain in IS as the slip level, but should be used with care in CLBP patients in selecting discogenic pain patients for fusion surgery, since the specificity of the test is not known and it may be positive for any origin of localized pain.     

Endocrine Therapy for Breast Cancer

Endocrine therapy is the primary treatment for the most common types of breast cancer. Endocrine agents work by inhibiting the tumor-stimulating effects of estrogen in hormone-sensitive tumors. A new class of targeted drugs synergize with endocrine agents to improve survival for patients with metastatic disease. Endocrine therapy is continued for years, and long-term survival is common, although toxicities often occur due to the alteration of the physiologic effects of estrogen. It is important, therefore, that primary care providers remain knowledgeable about patient needs during and after treatment.     

Clearing hepatitis C virus with direct antiviral agents reduces cardiovascular events in patients with prediabetes. Commentary to Sasso and colleagues

Liver health is a key determinant of cardiovascular risk (CVR). Hepatic fibrosis is the shared common result of chronic hepatitis, irrespective of aetiology. Fibrosis profoundly distorts liver tissue architecture and perturbs hepatic physiology, dictates the course of chronic liver disease and is increasingly recognized as a CVR factor. The relative weights of pre-diabetes and hepatic fibrosis as risk factors for major adverse cardiac events (MACE) in patients with HCV remain an open issue. Sasso and Colleagues answered this research question by treating approximately half of 770 HCV positive pre-diabetic patients with direct antiviral agents (DAAs), while the rest served as historical controls. Data have shown that achieving HCV clearance with DAAs was associated with a 60% reduced risk of MACE, thereby implying that this antiviral strategy is recommended in HCV positive pre-diabetic patients, regardless of the severity of liver disease and concurrent CVR factors. This study paves the way for additional studies addressing the molecular patho-mechanisms and changes in the clinical spectrum involved in cardio-metabolic protection following HCV eradication in patients with pre-diabetes.